4D pharma
- Country
- Ownership
- -
- Employees
- 88
- Market Cap
- -
- Introduction
4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.
RBX2660 Receives FDA Breakthrough Therapy Designation for Recurrent C. diff Infection
• RBX2660, a microbiota restoration therapy developed by Rebiotix and acquired by Ferring, has been granted Breakthrough Therapy Designation by the FDA for recurrent Clostridioides difficile infection.
• The drug aims to restore gut microbiome balance by transplanting live, human-derived microbes into the intestinal tract, offering a potential alternative to antibiotic treatments.
• Phase 3 trial data (PUNCH CD 3) demonstrated preliminary positive efficacy in reducing C. diff recurrence, positioning RBX2660 as a frontrunner in live microbiota-based therapies.
• RBX2660 has already been granted orphan drug and fast-track status, potentially expediting its path to market for patients with limited treatment options.
Multiple Sclerosis Pipeline Shows Promise with Novel Therapies in Development
• The multiple sclerosis (MS) therapeutic landscape is expanding, with over 80 active pipeline therapies currently in development by more than 75 companies.
• Recent clinical trials have yielded mixed results, with some therapies showing promise in specific MS subtypes, such as non-relapsing secondary progressive MS (nrSPMS).
• Regulatory milestones have been achieved, including FDA approval for new formulations and fast-track designations for therapies targeting progressive MS.
• Emerging therapies in the MS pipeline include monoclonal antibodies, oral treatments, and CAR-T cell therapies, offering diverse mechanisms of action and routes of administration.
© Copyright 2025. All Rights Reserved by MedPath